CN1516600A - 用于治疗肿瘤疾病的联合药物 - Google Patents

用于治疗肿瘤疾病的联合药物 Download PDF

Info

Publication number
CN1516600A
CN1516600A CNA028121880A CN02812188A CN1516600A CN 1516600 A CN1516600 A CN 1516600A CN A028121880 A CNA028121880 A CN A028121880A CN 02812188 A CN02812188 A CN 02812188A CN 1516600 A CN1516600 A CN 1516600A
Authority
CN
China
Prior art keywords
cyano
pyridyl
guanidine
hexyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028121880A
Other languages
English (en)
Chinese (zh)
Inventor
L
L·宾德若普
��������ķ������
E·布雷姆
�Ү��
P－J·V·耶内
K·J·汉贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN1516600A publication Critical patent/CN1516600A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028121880A 2001-05-24 2002-05-24 用于治疗肿瘤疾病的联合药物 Pending CN1516600A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US60/292,928 2001-05-24

Publications (1)

Publication Number Publication Date
CN1516600A true CN1516600A (zh) 2004-07-28

Family

ID=23126850

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028121880A Pending CN1516600A (zh) 2001-05-24 2002-05-24 用于治疗肿瘤疾病的联合药物

Country Status (17)

Country Link
US (1) US20030045515A1 (enExample)
EP (1) EP1411984B1 (enExample)
JP (1) JP2005508857A (enExample)
KR (1) KR20040007607A (enExample)
CN (1) CN1516600A (enExample)
AT (1) ATE394100T1 (enExample)
AU (1) AU2002316795B2 (enExample)
BR (1) BR0209936A (enExample)
CA (1) CA2449442A1 (enExample)
CZ (1) CZ20033189A3 (enExample)
DE (1) DE60226446D1 (enExample)
HU (1) HUP0400024A3 (enExample)
IL (1) IL158821A0 (enExample)
MX (1) MXPA03010691A (enExample)
PL (1) PL366462A1 (enExample)
RU (1) RU2291710C2 (enExample)
WO (1) WO2002094322A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253193B2 (en) * 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
PL372761A1 (en) * 2002-05-17 2005-08-08 Leo Pharma A/S Cyanoguanidine prodrugs
CN100503570C (zh) * 2002-05-17 2009-06-24 利奥制药有限公司 氰基胍前药
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
EP1838696B1 (en) * 2004-12-22 2016-03-09 Leo Pharma A/S Novel cyanoguanidine compounds
TWI380973B (zh) 2005-06-30 2013-01-01 Smithkline Beecham Corp 化合物
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2007014671A2 (de) * 2005-08-04 2007-02-08 Bayer Healthcare Ag KOMBINATIONEN MIT IKK-ß INHIBITOREN
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
AU2010210248B2 (en) * 2009-02-06 2012-08-16 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
CA2810049A1 (en) 2010-09-03 2012-03-08 Forma Tm, Llc Guanidine compounds and compositions for the inhibition of nampt
CA2990835A1 (en) 2015-06-23 2016-12-29 Case Western Reserve University Compositions and methods for treating cancer
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DK1175902T3 (da) * 1996-07-15 2005-12-19 Sankyo Co Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711122D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs

Also Published As

Publication number Publication date
CA2449442A1 (en) 2002-11-28
WO2002094322A2 (en) 2002-11-28
EP1411984A2 (en) 2004-04-28
CZ20033189A3 (cs) 2004-12-15
US20030045515A1 (en) 2003-03-06
ATE394100T1 (de) 2008-05-15
HUP0400024A2 (hu) 2004-04-28
AU2002316795B2 (en) 2007-08-02
RU2291710C2 (ru) 2007-01-20
JP2005508857A (ja) 2005-04-07
DE60226446D1 (de) 2008-06-19
MXPA03010691A (es) 2004-07-01
PL366462A1 (en) 2005-02-07
HUP0400024A3 (en) 2007-05-29
IL158821A0 (en) 2004-05-12
EP1411984B1 (en) 2008-05-07
KR20040007607A (ko) 2004-01-24
BR0209936A (pt) 2004-04-06
RU2003137006A (ru) 2005-04-10
WO2002094322A3 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
CN1516600A (zh) 用于治疗肿瘤疾病的联合药物
US7807682B2 (en) Pyridyl cyanoguanidine compounds
EP3277276B1 (en) Methods of administering glutaminase inhibitors
AU2002316795A1 (en) Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug
KR20130015669A (ko) 암의 재발 또는 전이의 억제용 약제학적 조성물
JP2020533332A (ja) 障害を処置するためのｃｘｃｒ−２阻害剤
EP2931296B1 (en) Treatment of diseases involving mucin
CN1662502A (zh) 氰基胍前药
RU2326867C2 (ru) Цианогуанидиновые производные, способ лечения и фармацевтическая композиция на их основе
US20150087886A1 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
US6642215B2 (en) Method of modulating NF-kB activity
JP2022533698A (ja) サイトカイン放出を治療、予防、阻害、又は低減する方法
HK1065260A (en) Combination medicament for treatment of neoplastic diseases
US8053446B2 (en) Cyanoguanidine compounds
KR102687556B1 (ko) 종양 전이를 억제하는 방법
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
WO2023109779A1 (zh) 杂环化合物用于减轻化疗药物引起的不良反应的用途
JP2008543769A (ja) （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン
HK1066216B (en) Novel pyridyl cyanoguanidine compounds
AU2002308264A1 (en) Novel pyridyl cyanoguanidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065260

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1065260

Country of ref document: HK